search
Back to results

Comparison of Amlodipine and Aliskiren in Diabetic Hypertensive Patient With Blood Pressure Not Controlled by Losartan

Primary Purpose

Hypertension, Diabetes Mellitus

Status
Withdrawn
Phase
Phase 4
Locations
Brazil
Study Type
Interventional
Intervention
Aliskiren
Amlodipine
Sponsored by
Hospital Universitario Pedro Ernesto
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension, Diabetes Mellitus, Vascular stiffness, Endothelial function

Eligibility Criteria

40 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Ambulatorial patients with age between 40 and 70 years-old.
  • Systemic arterial hypertension previously diagnosed and in use of two or less anti-hypertensive drugs in the preceding 4 weeks.
  • Those patients without anti-hypertensive drug prescribed in the last 4 weeks with office systolic blood pressure between 140 and 159 mmHg and diastolic between 90 and 109 mmHg.
  • Type 2 diabetes mellitus in use of oral medication that were not changed in the preceding 4 weeks. Glycated hemoglobin A1c less than 9.0%.
  • Accepted the consent form.

Exclusion Criteria:

  • Office systolic blood pressure equal or more than 180 mmHg, with or without treatment
  • Office diastolic blood pressure equal or more than 110 mmHg, with or without treatment
  • Evidences of a secondary cause for hypertension
  • Glycated hemoglobin A1c > 9.0%
  • Insulin therapy
  • Chronic kidney disease of level 3 to 5 or in dialysis
  • Advanced target organ lesion, obtained by history or additional exams, and defined by: previous myocardial infarction, heart failure with ejection fraction less than 40%, cerebral vascular accident (ischemic or hemorrhagic), peripheral vascular disease (claudication or doppler with obstruction > 50% of vascular lumen), retinopathy with visual loss, symptomatic neuropathy.
  • Cardiac arrhythmias, except for ectopic beats
  • Any clinical or disabling condition that, in the opinion of the investigators, may confound or prejudice study results.

Sites / Locations

  • Hospital Universitario Pedro Ernesto

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Aliskiren

Amlodipine

Arm Description

Outcomes

Primary Outcome Measures

Vascular stiffness
Vascular stiffness will be measured by pulse wave velocity and augmentation index and compared between anlodipine and aliskiren.
Endothelial function
Access endothelial function by peripheral arterial tonometry and brachial flow-mediated vasodilation and compare it between anlodipine and aliskiren.
Renin activity and concentration
Access plasma renin activity and concentration and compare it between anlodipine and aliskiren.

Secondary Outcome Measures

Compare drug effects in office blood pressure measurements to those obtained by home blood pressure monitoring and ambulatory blood pressure monitoring
Compare drug effects in office blood pressure measurements to those obtained by home blood pressure monitoring and ambulatory blood pressure monitoring
Assess drugs effects in renin-angiotensin-aldosterone system (RAAS) and correlate it to renin concentration/mass and plasmatic renin activity
Assess drugs effects in RAAS and correlate it to renin concentration/mass and plasmatic renin activity
Correlation of drug effects and uric acid plasmatic concentration
Correlation of drug effects and uric acid plasmatic concentration
Correlation of drug effects and glomerular filtration rate
Correlation of drug effects and glomerular filtration rate
Correlation of drug effects and microalbuminuria
Correlation of drug effects and microalbuminuria
Correlation of drug effects and left ventricular mass and function (systolic and diastolic)
Correlation of drug effects and left ventricular mass and function (systolic and diastolic)

Full Information

First Posted
August 1, 2011
Last Updated
March 5, 2012
Sponsor
Hospital Universitario Pedro Ernesto
Collaborators
Novartis
search

1. Study Identification

Unique Protocol Identification Number
NCT01409408
Brief Title
Comparison of Amlodipine and Aliskiren in Diabetic Hypertensive Patient With Blood Pressure Not Controlled by Losartan
Official Title
Comparison Between Amlodipine and Aliskiren in Diabetic Hypertensive Patient With Blood Pressure Not Controlled by Losartan: Effects on Endothelial Function and Renin Concentration and Activity
Study Type
Interventional

2. Study Status

Record Verification Date
April 2011
Overall Recruitment Status
Withdrawn
Why Stopped
Due to preliminary results of Altitude Trial.
Study Start Date
April 2011 (undefined)
Primary Completion Date
April 2013 (Anticipated)
Study Completion Date
December 2013 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Hospital Universitario Pedro Ernesto
Collaborators
Novartis

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Assess if aliskiren is capable of enhancing vascular stiffness and endothelial function and compare theses effects and renin activity and concentration to those obtained with a calcium channel blocker, amlodipine, in patients with diabetes mellitus type 2 and blood pressure not controlled by 100 mg per day of losartan.
Detailed Description
Hypertension and diabetes mellitus are important risk factors for cardiovascular morbidity and mortality. Endothelial dysfunction and vascular rigidity are two pathophysiological mechanisms that may explain this relationship. Recent publications showed that both ACEi (angiotensin converting enzyme inhibitor) and ARB (angiotensin receptor blocker) were capable of improving vascular stiffness and endothelial function, and that these effects occurred despite blood pressure reduction. The major debate that persists is which drug to associate with ACEi or ARB to achieve blood pressure control in diabetic patients. Recent studies showed that even in patients under ACEi or ARB therapy there may be residual activity in the renin-angiotensin-aldosterone system (RASS). Direct renin inhibitors (DRI) are a new class of anti-hypertensive drugs that may complement the blockade of the RASS. Aliskiren was the first drug of this class that completed phase 3 studies and marketed in the 21th century. It's main advantage is that DRI may reduce angiotensin II and aldosterone synthesis without increasing renin levels. This study main objective is to assess if aliskiren is capable of enhancing vascular stiffness and endothelial function and compare theses effects to those obtained with a calcium channel blocker, amlodipine, in patients with diabetes mellitus type 2 and blood pressure not controlled by 100 mg per day of losartan. Vascular stiffness and endothelial function will be measured by: pulse wave velocity, augmentation index, brachial artery flow-mediated vasodilation, peripheral arterial tonometry (EndoPat). Another main objective is to compare plasma renin activity and concentration between those groups.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Diabetes Mellitus
Keywords
Hypertension, Diabetes Mellitus, Vascular stiffness, Endothelial function

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Aliskiren
Arm Type
Active Comparator
Arm Title
Amlodipine
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Aliskiren
Other Intervention Name(s)
Rasilez.
Intervention Description
300 mg of aliskiren daily for 8 weeks.
Intervention Type
Drug
Intervention Name(s)
Amlodipine
Other Intervention Name(s)
Norvasc.
Intervention Description
Amlodipine 5 mg daily for 8 weeks.
Primary Outcome Measure Information:
Title
Vascular stiffness
Description
Vascular stiffness will be measured by pulse wave velocity and augmentation index and compared between anlodipine and aliskiren.
Time Frame
8 weeks
Title
Endothelial function
Description
Access endothelial function by peripheral arterial tonometry and brachial flow-mediated vasodilation and compare it between anlodipine and aliskiren.
Time Frame
8 weeks
Title
Renin activity and concentration
Description
Access plasma renin activity and concentration and compare it between anlodipine and aliskiren.
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Compare drug effects in office blood pressure measurements to those obtained by home blood pressure monitoring and ambulatory blood pressure monitoring
Description
Compare drug effects in office blood pressure measurements to those obtained by home blood pressure monitoring and ambulatory blood pressure monitoring
Time Frame
8 weeks
Title
Assess drugs effects in renin-angiotensin-aldosterone system (RAAS) and correlate it to renin concentration/mass and plasmatic renin activity
Description
Assess drugs effects in RAAS and correlate it to renin concentration/mass and plasmatic renin activity
Time Frame
8 weeks
Title
Correlation of drug effects and uric acid plasmatic concentration
Description
Correlation of drug effects and uric acid plasmatic concentration
Time Frame
8 weeks
Title
Correlation of drug effects and glomerular filtration rate
Description
Correlation of drug effects and glomerular filtration rate
Time Frame
8 weeks
Title
Correlation of drug effects and microalbuminuria
Description
Correlation of drug effects and microalbuminuria
Time Frame
8 weeks
Title
Correlation of drug effects and left ventricular mass and function (systolic and diastolic)
Description
Correlation of drug effects and left ventricular mass and function (systolic and diastolic)
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ambulatorial patients with age between 40 and 70 years-old. Systemic arterial hypertension previously diagnosed and in use of two or less anti-hypertensive drugs in the preceding 4 weeks. Those patients without anti-hypertensive drug prescribed in the last 4 weeks with office systolic blood pressure between 140 and 159 mmHg and diastolic between 90 and 109 mmHg. Type 2 diabetes mellitus in use of oral medication that were not changed in the preceding 4 weeks. Glycated hemoglobin A1c less than 9.0%. Accepted the consent form. Exclusion Criteria: Office systolic blood pressure equal or more than 180 mmHg, with or without treatment Office diastolic blood pressure equal or more than 110 mmHg, with or without treatment Evidences of a secondary cause for hypertension Glycated hemoglobin A1c > 9.0% Insulin therapy Chronic kidney disease of level 3 to 5 or in dialysis Advanced target organ lesion, obtained by history or additional exams, and defined by: previous myocardial infarction, heart failure with ejection fraction less than 40%, cerebral vascular accident (ischemic or hemorrhagic), peripheral vascular disease (claudication or doppler with obstruction > 50% of vascular lumen), retinopathy with visual loss, symptomatic neuropathy. Cardiac arrhythmias, except for ectopic beats Any clinical or disabling condition that, in the opinion of the investigators, may confound or prejudice study results.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ronaldo A Gismondi, MD, DsC
Organizational Affiliation
HUPedroernesto (UERJ)
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mario F Neves, MD, PhD
Organizational Affiliation
HUPedroernesto (UERJ)
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Wille Oigman, MD, PhD
Organizational Affiliation
HUPedroernesto (UERJ)
Official's Role
Study Chair
Facility Information:
Facility Name
Hospital Universitario Pedro Ernesto
City
Rio de Janeiro
ZIP/Postal Code
20551030
Country
Brazil

12. IPD Sharing Statement

Learn more about this trial

Comparison of Amlodipine and Aliskiren in Diabetic Hypertensive Patient With Blood Pressure Not Controlled by Losartan

We'll reach out to this number within 24 hrs